Click here for Inflectra® (infliximab) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
What is a biosimilar
The future of biosimilars
Considerations for biologic switching
Adoption and use of biosimilars may help increase choice and potentially drive cost savings by stimulating competition between orginator biologics and their respective biosimilars as well as between biosimilars themselves.1
A competitive and sustainable marketplace that supports both the orginator biologics and biosimilars is necessary to obtain the benefits that those important medicines offer for patients, physicians, payers and healthcare systems.2
Learn more about TDM and biomarkers
Inflammatory bowel disease
Infliximab mechanism of action
Support & Resources
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020